Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02906813 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02906813 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 9 participants.
The verdict
NCT02906813, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the relative bioavailability (BA) of 300 milligram (mg) TAK-935 tablets compared to 300 mg of TAK-935 solution and to determine the effect of food on the BA of TAK-935 300 mg tablets in healthy adult participants.
Interventions
- DRUG TAK-935 Tablets
- DRUG TAK-935 Oral Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-09-12 |
| Est. Completion | 2016-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02906813
The ClinicalTrials.gov registry entry for NCT02906813 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-935 Tablets is the first listed.
NCT02906813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02906813 about?
NCT02906813 is a clinical study titled "A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants". The purpose of this study is to assess the relative bioavailability (BA) of 300 milligram (mg) TAK-935 tablets compared to 300 mg of TAK-935 solution and to determine the effect of food on the BA of TAK-935 300 mg tablets in healthy adult participants.
What is the current status of trial NCT02906813?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-09-12. Estimated completion is 2016-11-09.
What interventions are being tested in trial NCT02906813?
The interventions under investigation include: TAK-935 Tablets (DRUG), TAK-935 Oral Solution (DRUG).
Who is sponsoring clinical trial NCT02906813?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.